People: CRISPR Therapeutics AG (CRSP.OQ)

CRSP.OQ on NASDAQ Stock Exchange Global Market

15 Nov 2019
Change (% chg)

$1.81 (+3.29%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Terrett, Jon 

Dr. Jon Terrett, Ph.D., serves as Head of Immuno-Oncology Research and Translation at CRISPR Therapeutics Ltd. Prior to joining CRISPR Therapeutics, he was the Vice President of oncology discovery for CytomX, a U.S.-based biotechnology company focused on developing drugs to treat different types of cancer. In addition, he has held various R&D leadership roles in biopharma, including serving as the Chief Scientific Officer at Oxford Biotherapeutics, and as a director at various biotechnology companies including Medarex, CellTech and Oxford Glycosciences. He received a B.S. in genetics at the University of Sheffield and a doctorate in genetics at the University of Nottingham.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --